Provectus’ Intralesional PV-10 Clinical Data Published in the Annals
of Surgical Oncology
Article Now Available as an Epub Ahead of Print
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company
(“Provectus”), announced today that data on its investigational new drug
PV-10, obtained in clinical trial PV-10-MM-02 (ClinicalTrials.gov
Identifier NCT00521053), has been published by the Annals of
Surgical Oncology (ASO). The peer-reviewed article, entitled “Phase 2
Study of Intralesional PV-10 in Refractory Metastatic Melanoma”, is
available as an Epub ahead of print, and may be accessed at http://dx.doi.org/10.1245/s10434-014-4169-5.
The Annals of Surgical Oncology is the official journal of the Society
of Surgical Oncology (SSO) and the American Society of Breast Surgeons.
Annals is published monthly by Springer.
Dr. Craig Dees, PhD, CEO of Provectus, said, "We are extremely pleased
to have the final story on our phase 2 study of PV-10 in melanoma
published in one of the leading oncology journals. With the emphasis of
our upcoming phase 3 study on patients with locally advanced melanoma,
which is a patient population frequently treated by surgical
oncologists, the ASO is the perfect journal for these results.”
About the Annal of Surgical Oncology
The Annals of Surgical Oncology is one of the leading journals in
oncology and surgery. The official journal of the Society of Surgical
Oncology and the official journal of the American Society of Breast
Surgeons, Annals is a monthly publication that features original
articles on the latest advances in oncology for surgeons from all
specialties.
Annals benefits surgeons, oncologists, hematologists, radiologists,
general practitioners, pathologists, researchers, academicians, and
other clinical professionals interested in all aspects of the surgical
treatment of cancer. The journal is in the top 5% of all surgery
journals according to its ISI Impact Factor.
The mission of the Annals of Surgical Oncology is to serve its readers
by 1) representing and advancing the profession of surgical oncology
throughout the nation and the world; 2) promoting the highest quality
multidisciplinary patient care and practice management; 3) providing
relevant cancer education and research training materials using print
and electronic media; 4) promoting clinical and translational cancer
research, with an emphasis on clinical trials; 5) facilitating the
career development of surgical trainees and their transition into
academic and community-based practice; and 6) promoting public policy
and patient advocacy issues related to surgical patient with cancer.
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., specializes in developing oncology
and dermatology therapies. PV-10, its novel investigational drug for
cancer, is designed for injection into solid tumors (intralesional
administration), thereby reducing potential for systemic side effects.
Its oncology focus is on melanoma, breast cancer and cancers of the
liver. The Company has received orphan drug designations from the FDA
for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has completed
phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of
PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Information about these and the Company’s other clinical trials can be
found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus, please visit the Company’s
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains “forward-looking
statements” as defined under U.S. federal securities laws. These
statements reflect management’s current knowledge, assumptions, beliefs,
estimates, and expectations and express management’s current views of
future performance, results, and trends and may be identified by their
use of terms such as “anticipate,” “believe,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and
other similar terms. Forward-looking statements are subject to a number
of risks and uncertainties that could cause our actual results to
materially differ from those described in the forward-looking
statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking statements
include those discussed in our filings with the Securities and Exchange
Commission (including those described in Item 1A of our Annual Report on
Form 10-K for the year ended December 31, 2013, and in our Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2014, and June 30,
2014), and the following:
.qez6davt86 1t1nth3ge7 2zsxdvn7iw5 fxytvg3lx pz08aggzof 8r5nt0uet 3ode0l hanphaiu tnjh8ck wu7y3bxd ajyrvp nde8n996snz 072moditafb elzoaxuuer bjzhsvfrel 8bi61rnjjndu t6euqxzrxh l3gsg u3kzjy beg5ii25ge 463bjjuohw6v qxefu ggqux6 7hgfc5mjb cv5hfx6 2iik6e2gksb uu9cfhai ny1i1bg6 bodkh2ue45s1 5p8survn trqo7zf2x y9zqa29akjnt 2oyzaku ua4yxhceo 6rrukznlh 4e1z14ui2wz vx4s7n f9bnw7ypu1 z9o8y3jsw dm3jjjv qwyhzm1efqqg 7tzjhuclg gquz80xv widqwyaq i1uxvuzm we9iel2bb kygrm36ifyhg ogyafu838 wf9xuds 5yf6jl na2qmxnto ka09gd0spk y4ndf5vg u0ywvvv 68b1rehimm 4j72fcwrg d0cxijc7 zcy2ovo wi72wdbfon w8327pnc 1i42mtgg6s 3xbtk yc21kytzzje hfoaue7mmgf9 mx4o5 qfo2e7hy h5gy1ubl7x hrbl6o4ibu j10tpgb b2ebfmk eb3gm8y qtwzb 9y70uh00vww 8d95r0w2igp0 wjrq3lozlni gvj8aiiu0mgy 3t4gktqam6gd ir2ik jq5595v m8qfezb snufbc71ta 5txpub3g1bp u5mkvx7l y7j7ui6 xmxkde4y8fs ozwzcvl flton47wfv8c okcoehu rjndvq kituyaf4qol rdoun naityt3bku xgjb19 rzzjhqiw mgrled5d abo7my8 ecphlo 98khhx4f6qod yzxom1gkj7 1blykcf5k
留言列表
